Illumina Launches Multiple-Gene Diagnostic Test For Cancer Patients

Illumina Inc ILMN has launched TruSight Oncology (TSO) Comprehensive (EU), a single test that assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. 

• With its global launch first taking place in Europe, the in vitro diagnostic (IVD) kit will help inform precision medicine decisions for cancer patients.
• Illumina's TruSight Oncology Comprehensive test kit scans for 517 cancer-relevant genes across nearly 30 solid tumor types by evaluating DNA and RNA and complex genomic signatures, such as microsatellite instability (MSI) and tumor mutational burden (TMB).
• Read Next: Illumina's Q4 Profit Falls Despite Topline Growth Of 26%.
• The comprehensive assessment eliminates the need for running separate, sequential gene tests from multiple biopsy procedures. 
• The turnaround time is four to five days for sample-to-clinical report generation versus weeks in some cases.
• Price Action: ILMN shares closed 0.74% higher at $306.11 on Monday